Drug Shortage Report for MAGNESIUM SULFATE INJECTION, USP

Last updated on 2023-01-20 History
Report ID 159333
Drug Identification Number 02139499
Brand name MAGNESIUM SULFATE INJECTION
Common or Proper name Magnesium Sulfate Injection
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) MAGNESIUM SULFATE
Strength(s) 500MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 10mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2022-05-01
Actual start date 2022-05-01
Estimated end date 2022-12-16
Actual end date 2022-12-05
Shortage status Resolved
Updated date 2023-01-20
Company comments Fresenius Kabi Canada regrets to advise that due to production delays we will be encountering a supply interruption on our Magnesium Sulfate Injection, USP 500 mg/mL SD Vial 10 mL effective May 1, 2022 until December 16, 2022. Effective May 1, 2022 allocations of 50mL will be increased to cover 100% of 50mL demand plus 200% of 10mL demand on a mL:mL basis
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v13 2023-01-20 English Compare
v12 2022-12-06 English Compare
v11 2022-12-05 French Compare
v10 2022-12-05 English Compare
v9 2022-10-19 French Compare
v8 2022-10-19 English Compare
v7 2022-08-25 English Compare
v6 2022-07-07 French Compare
v5 2022-07-07 English Compare
v4 2022-07-07 English Compare
v3 2022-05-02 English Compare
v2 2022-04-22 French Compare
v1 2022-04-22 English Compare

Showing 1 to 13 of 13